<DOC>
	<DOCNO>NCT00597584</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy peginesatide maintenance treatment anemia participant dialysis .</brief_summary>
	<brief_title>Safety &amp; Efficacy Peginesatide Maintenance Treatment Anemia Participants With Chronic Kidney Disease Hemodialysis</brief_title>
	<detailed_description>Anemia associate chronic kidney disease due several factor , primarily inability diseased kidney produce adequate amount endogenous erythropoietin . Ancillary factor include shorten lifespan red blood cell , iron nutritional deficiency , infection , inflammation . The presence severity anemia related duration extent kidney failure . Anemia associate increased mortality , increase likelihood hospitalization , reduce cognitive function , increase leave ventricular hypertrophy heart failure . Erythropoiesis stimulate agent ( ESAs ) establish treatment anemia chronic renal failure subject , improve management anemia alternative transfusion . Peginesatide parenteral formulation develop treatment anemia patient chronic kidney disease . Peginesatide bind activate human erythropoietin receptor stimulate erythropoiesis human red cell precursor manner similar know erythropoiesis-stimulating agent . Eligible participant randomize 2:1 ratio peginesatide administer every 4 week continue treatment epoetin administer 1-3 time week , respectively . Total commitment time study 4 week screen follow minimum 52 week study treatment . To evaluate cardiovascular safety peginesatide injection , composite safety endpoint ( CSE ) define use prospectively plan analysis combine cardiovascular safety data four Phase 3 peginesatide injection study ( NCT00598273 , NCT00597753 , NCT00598442 , NCT00597584 ) . The CSE consist six event : death , stroke , myocardial infarction , serious adverse event congestive heart failure , unstable angina , arrhythmia . An independent Event Review Committee ( ERC ) use provide blind adjudication potential CSE event .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Inclusion Criteria 1 . Participants chronic renal failure hemodialysis ≥ 3 month prior randomization . 2 . On IV epoetin alfa beta maintenance therapy continuously prescribe minimum 8 week prior randomization . 3 . Four consecutive hemoglobin value mean ≥ 10.0 ≤ 12.0 g/dL Screening Period . Exclusion Criteria 1 . Females pregnant breastfeeding . 2 . Known intolerance erythropoiesis stimulate agent pegylated molecule parenteral iron supplementation product . 3 . Known bleed coagulation disorder . 4 . Known hematologic disease cause anemia renal disease 5 . Poorly control hypertension . 6 . Evidence active malignancy within one year prior randomization . 7 . Temporary ( untunneled ) dialysis access catheter . 8 . A scheduled kidney transplant . 9 . A scheduled surgery may expect lead significant blood loss .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>dialysis</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide™</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>